comparemela.com
Home
Live Updates
Johnson Innovative - Breaking News
Pages:
6
7
8
9
10
11
12
Latest Breaking News On - Johnson innovative - Page 5 : comparemela.com
Johnson & Johnson submits regulatory applications to
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK.
Japan
United-kingdom
Canada
Belgium
Beerse
Region-flamande
Canadian
David-lee
Sophie-daneau
Drug-administration
Johnson
Japan-pharmaceuticals
New to the Market - Life Sciences IPOs; (Nasdaq: MNDR) (NYSE: PACS) (Nasdaq: CTNM)
New to the Market - Life Sciences IPOs; (Nasdaq: MNDR) (NYSE: PACS) (Nasdaq: CTNM)
United-states
Nasdaq
Youtube
Facebook
Ul-solutions-inc
Twitter
Contineum-therapeutics-inc
Massimo-group-nasdaq
Group-inc
Asia-pacific-companies
Ul-solutions
Johnson & Johnson receives positive CHMP opinion for
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of.
Singapore
Belgium
Saclay
France-general
France
Beerse
Region-flamande
United-states
American
Nicolas-girard
Henar-hevia
Institut-curie
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Media contact: Investor contact: .
France
Beerse
Region-flamande
Belgium
Saclay
France-general
Institut-curie
Henar-hevia
Nicolas-girard
Zayn-qureshi
European-medicines-agency
Johnson
Global Oncology Precision Medicine Market Trends and
Dublin, April 23, 2024 (GLOBE NEWSWIRE) The
Dublin
Ireland
Spain
France
Germany
Canada
Israel
Italy
United-states
China
Chile
Argentina
vimarsana © 2020. All Rights Reserved.